Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.51 |
| ▸ | DRD4 | P21917 | 8/20 | 0.51 |
| ▸ | DRD3 | P35462 | 7/20 | 0.51 |
| ▸ | HTR1A | P08908 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13404452 | 0.90 | TSHR (0.58) | DRD2DRD4DRD3HTR1AALDH1A1 | |
| SCHEMBL13404501 | 0.90 | HTR3E (0.54) | DRD2DRD4DRD3HTR1AALDH1A1 | |
| SCHEMBL13404401 | 0.83 | HTR1A (0.47) | DRD2DRD4DRD3HTR1A | |
| SCHEMBL13404400 | 0.77 | DRD2 (0.51) | DRD2DRD4DRD3HTR1AALDH1A1 | |
| SCHEMBL13404396 | 0.73 | ALDH1A1 (0.50) | HTR1AALDH1A1TSHR | |
| SCHEMBL13889793 | 0.72 | TSHR (0.55) | ALDH1A1TSHR | |
| SCHEMBL13404470 | 0.71 | GRM2 (0.50) | DRD2 | |
| SCHEMBL13940607 | 0.71 | ALDH1A1 (0.61) | DRD2DRD4HTR1AALDH1A1 | |
| SCHEMBL13404436 | 0.71 | MCHR1 (0.47) | DRD2DRD4DRD3 | |
| SCHEMBL5239845 | 0.71 | HTR3E (0.43) | DRD2DRD4DRD3HTR1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105694-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105694-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, CHRNA5, ADRB2 | DRD2 34/4885DRD4 58/4885DRD3 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.